Combined mannitol and deferoxamine therapy for myohemoglobinuric renal injury and oxidant tubular stress. Mechanistic and therapeutic implications.

Mannitol (M) and deferoxamine (DFO) can each protect against myohemoglobinuric acute renal failure (MH-ARF). This study assessed M-DFO interactions during MH-ARF to help discern mechanisms of renal injury, and to define whether M + DFO exerts additive or synergistic antioxidant/cytoprotective effect...

Cijeli opis

Bibliografski detalji

Izdano u:	J Clin Invest
Glavni autor:	Zager, R A
Format:	Artigo
Jezik:	Inglês
Izdano:	American Society for Clinical Investigation 1992
Teme:	Research Article
Online pristup:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC329921/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1325995/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI115942
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!